Aligos Therapeutics (NASDAQ:ALGS) Coverage Initiated by Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group started coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research note issued on Thursday. The brokerage set a “buy” rating and a $48.00 price target on the stock.

A number of other analysts have also commented on ALGS. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group began coverage on shares of Aligos Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Aligos Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $6.95 on Thursday. The firm has a market capitalization of $43.02 million, a price-to-earnings ratio of -0.81 and a beta of 2.67. The business’s fifty day moving average price is $7.59 and its two-hundred day moving average price is $8.90. Aligos Therapeutics has a 52 week low of $3.76 and a 52 week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. As a group, research analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. increased its stake in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new position in Aligos Therapeutics in the third quarter valued at about $98,000. Susquehanna International Group LLP bought a new stake in shares of Aligos Therapeutics in the third quarter worth about $99,000. XTX Topco Ltd bought a new position in shares of Aligos Therapeutics during the 2nd quarter valued at about $100,000. Finally, HRT Financial LP bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at about $106,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.